Patents Represented by Attorney Arnold & Porter LLP
  • Patent number: 7220780
    Abstract: The present invention relates to pharmaceutical compositions and methods for treating a retinal disorder or glaucoma using NAALADase inhibitors.
    Type: Grant
    Filed: May 30, 2001
    Date of Patent: May 22, 2007
    Assignee: Guilford Pharmaceuticals Inc.
    Inventors: Barbara S. Slusher, Krystyna Wozniak
  • Patent number: 7214786
    Abstract: Recombinant polynucleotides and recombinant polypeptides useful for improvement of plants are provided. The disclosed recombinant polynucleotides and recombinant polypeptides find use in production of transgenic plants to produce plants having improved properties.
    Type: Grant
    Filed: November 6, 2003
    Date of Patent: May 8, 2007
    Inventors: David K. Kovalic, Scott E. Andersen, Joseph R. Byrum, Timothy W. Conner, James D. Masucci, Yihua Zhou
  • Patent number: 7205397
    Abstract: A protein which inhibits osteoclast differentiation and/or maturation and a method for producing the protein. The protein is produced by human embryonic lung fibroblasts and has a molecular weight of about 60 kD and about 120 kD under non-reducing conditions and about 60 kD under reducing conditions on SDS-polyacrylamide gel electrophoresis. The protein can be isolated and purified from the culture medium of fibroblasts. Furthermore, the protein can be produced by gene engineering. The present invention includes cDNA for producing the protein by gene engineering, antibodies having specific affinity for the protein or a method for determining protein concentration using these antibodies.
    Type: Grant
    Filed: April 17, 1998
    Date of Patent: April 17, 2007
    Assignee: Sankyo, Co., Ltd.
    Inventors: Masaaki Goto, Eisuke Tsuda, Shin′ichi Mochizuki, Kazuki Yano, Fumie Kobayashi, Nobuyuki Shima, Hisataka Yasuda, Nobuaki Nakagawa, Tomonori Morinaga, Masatsugu Ueda, Kanji Higashio
  • Patent number: 7192718
    Abstract: The present invention relates to a novel protein which binds to Osteoclastogenesis Inhibitory Factor (OCIF-binding molecule; OBM), a process for preparing the same, DNA encoding said protein, a protein having an amino acid sequence encoded by this DNA, a method for producing said protein by genetic engineering technique, and a pharmaceutical composition containing said protein. In addition, screening methods for a substance for controlling expression of said protein using said protein and the DNA, a substance which inhibits or protein through binding to said protein, the substance obtained by the screening methods, and a pharmaceutical composition which contains this substance are disclosed. An antibody for said protein, a process for preparing the same, a measuring method of said protein using the antibody, and a medicine comprising the antibody are also disclosed.
    Type: Grant
    Filed: June 13, 2003
    Date of Patent: March 20, 2007
    Assignee: Sankyo Co. Ltd
    Inventors: Kyoji Yamaguchi, Hisataka Yasuda, Nobuaki Nakagawa, Nobuyuki Shima, Masahiko Kinosaki, Eisuke Tsuda, Masaaki Goto, Kazuki Yano, Akihiro Tomoyasu, Fumie Kobayashi, Naohiro Washida, Ken Takahashi, Tomonori Morinaga, Kanji Higashio
  • Patent number: 7166771
    Abstract: The present invention is directed to nucleic acid molecules and nucleic acid constructs, and other agents associated with simultaneous up- and down-regulation of expression of RNAs. Specifically it includes methods of simultaneously enhancing the expression of a first RNA at the same time as suppressing the expression of a second RNA. The present invention also specifically provides constructs capable of simultaneously enhancing the expression of a first RNA while at the same time suppressing the expression of a second RNA, methods for utilizing such agents and plants containing such agents. The present invention also provides other constructs including polycistronic constructs.
    Type: Grant
    Filed: September 24, 2003
    Date of Patent: January 23, 2007
    Assignee: Monsanto Technology LLC
    Inventors: Alison Van Eenennaam, Christine K. Shewmaker
  • Patent number: 7163610
    Abstract: A series of low molarity conductive media based on non-buffering univalent cations, such as sodium chloride-sodium acetate (SCA), sodium boric acid (SB), lithium boric acid, and lithium acetate mitigate the “runaway” positive feedback heating loop produced by conventional media containing biological amine buffers and permit improved DNA electrophoresis under the conditions of low salt concentration. These media serve well in ultra-fast DNA electrophoresis and in high-resolution separations of RNA and DNA fragments.
    Type: Grant
    Filed: November 4, 2004
    Date of Patent: January 16, 2007
    Assignee: Faster Better Media LLC
    Inventors: Scott E. Kern, Jonathan R. Brody
  • Patent number: 7164059
    Abstract: The present invention is a novel method which improves the economical production of seedless watermelon fruit. The novel method involves using short vine pollinators in the production field to pollinate the triploid hybrids which result in increased yields.
    Type: Grant
    Filed: April 23, 2003
    Date of Patent: January 16, 2007
    Assignee: Seminis Vegetable Seeds, Inc.
    Inventor: Warren S. Barham
  • Patent number: 7154021
    Abstract: The present invention is in the field of soybean genetics. More specifically, the invention relates to nucleic acid molecules from regions the soybean genome, which are associated with soybean cyst nematode resistance. The invention also relates to proteins encoded by such nucleic acid molecules as well as antibodies capable of recognizing these proteins. The invention also relates to nucleic acid markers from regions the soybean genome, which are associated with soybean cyst nematode resistance. Moreover, the invention relates to uses of such molecules, including, transforming soybean cyst nematode resistant soybean with constructs containing nucleic acid molecules from regions the soybean genome, which are associated with soybean cyst nematode resistance. Furthermore, the invention relates to the use of such molecules in a plant breeding program.
    Type: Grant
    Filed: January 5, 2001
    Date of Patent: December 26, 2006
    Assignee: Monsanto Technology LLC
    Inventors: Brian M. Hauge, Ming Li Wang, Jeremy David Parsons, Laurence David Parnell
  • Patent number: 7148250
    Abstract: This invention relates to new compounds, pharmaceutical compositions and diagnostic kits comprising such compounds, and methods of using such compounds for inhibiting NAALADase enzyme activity, detecting diseases where NAALAdase levels are altered, effecting neuronal activity, effecting TGF-? activity, inhibiting angiogenesis, and treating glutamate abnormalities, neuropathy, pain, compulsive disorders, prostate diseases, cancers and glaucoma.
    Type: Grant
    Filed: December 19, 2002
    Date of Patent: December 12, 2006
    Assignee: Guilford Pharmaceuticals Inc.
    Inventors: Takashi Tsukamoto, Brian Grella, Pavel Majer
  • Patent number: 7149679
    Abstract: A method and apparatus for creating a complex process model for use in a graphical environment, with the process utilizing defined entities including places, transitions, and arcs. Places represent data types, transitions represent actions, and arcs represent the connection of places and transitions. The places, transitions, and arcs may be interchanged by the user without the need to recreate the entire model. The invention also includes a method and apparatus of simulating a complex process, by identifying the attributes and values of the places and transitions, identifying the parameters of the connecting arcs, and manipulating the places, transitions, and arcs to constitute a process in action.
    Type: Grant
    Filed: December 12, 2003
    Date of Patent: December 12, 2006
    Assignee: Expand, Inc.
    Inventor: John Woodring
  • Patent number: 7148336
    Abstract: By this invention, novel nucleic acid sequences are provided, wherein said nucleic acid sequence is a genomic sequence of a plant desaturase encoding sequence. Also provided in the present invention are the promoter and intron sequences of the desaturase genomic sequences. Furthermore, recombinant DNA constructs employing the polynucleotide sequences are provided. The instant invention also provides methods for the modification of fatty acid compositions in host plant cells.
    Type: Grant
    Filed: October 11, 2002
    Date of Patent: December 12, 2006
    Assignee: Calgene LLC
    Inventor: Joanne Fillatti
  • Patent number: 7138543
    Abstract: The present invention relates to new thiolalkyl benzoic acids, pharmaceutical compositions and diagnostic kits comprising such compounds, and methods of using such compounds for inhibiting NAALADase enzyme activity, detecting diseases where NAALADase levels are altered, effecting neuronal activity, effecting TGF-? activity, inhibiting angiogenesis, and treating glutamate abnormalities, neuropathy, pain, compulsive disorders, prostate diseases, cancers, glaucoma, retinal disorders, and cancer.
    Type: Grant
    Filed: April 7, 2004
    Date of Patent: November 21, 2006
    Assignee: Guilford Pharmaceuticals Inc.
    Inventors: Takashi Tsukamoto, Doris Stoermer, Dilrukshi Vitharana
  • Patent number: 7138275
    Abstract: The invention relates to the production of adult dedifferentiated, programmable stem cells from human monocytes by cultivation of monocytes in a culture medium which contains M-CSF and IL-3. The invention further relates to pharmaceutical preparations, which contain the dedifferentiated, programmable stem cells and the use of these stem cells for the production of target cells and target tissue.
    Type: Grant
    Filed: March 28, 2003
    Date of Patent: November 21, 2006
    Assignee: Blasticon Biotechnologische Forschung GmbH
    Inventors: Bernd Karl Friedrich Kremer, Fred Fändrich, Maren née Schulze Ruhnke
  • Patent number: 7125686
    Abstract: A protein which inhibits osteoclast differentiation and/or maturation and a method for producing the protein. The protein is produced by human embryonic lung fibroblasts and has a molecular weight of about 60 kD and about 120 kD under non-reducing conditions and about 60 kD under reducing conditions on SDS-polyacrylamide gel electrophoresis. The protein can be isolated and purified from the culture medium of fibroblasts. Furthermore, the protein can be produced by gene engineering. The present invention includes cDNA for producing the protein by gene engineering, antibodies having specific affinity for the protein or a method for determining protein concentration using these antibodies.
    Type: Grant
    Filed: August 20, 1997
    Date of Patent: October 24, 2006
    Assignee: Sankyo Co., Ltd.
    Inventors: Masaaki Goto, Eisuke Tsuda, Shin'ichi Mochizuki, Kazuki Yano, Fumie Kobayashi, Nobuyuki Shima, Hisataka Yasuda, Nobuaki Nakagawa, Tomonori Morinaga, Masatsugu Ueda, Kanji Higashio
  • Patent number: 7125907
    Abstract: This invention provides new compounds, pharmaceutical compositions and diagnostic kits comprising such compounds, and methods of using such compounds for inhibiting NAALADase enzyme activity, detecting diseases where NAALADase levels are altered, inhibiting angiogenesis, effecting a TGF-? activity or a neuronal activity, and treating a glutamate abnormality, a compulsive disorder, neuropathy, pain, a prostate disease, cancer, Huntington's disease, diabetes, a retinal disorder or glaucoma.
    Type: Grant
    Filed: March 3, 2004
    Date of Patent: October 24, 2006
    Assignee: Guilford Pharmaceuticals Inc.
    Inventors: Barbara S. Slusher, Takashi Tsukamoto
  • Patent number: 7125670
    Abstract: The invention provides ligands and fragments thereof to a receptor on the surface of activated CD4+ T-cells. An exemplary ligand is designated ACT-4-L-h-1. Preferred fragments include purified extracellular domains of ligands. The invention also provides humanized and human antibodies to the ligand. The invention further provides methods of using the ligand and the antibodies in treatment of diseases and conditions of the immune system. The invention also provides methods of monitoring activated CD4+ T-cells using the ligands or fragments thereof.
    Type: Grant
    Filed: December 23, 2002
    Date of Patent: October 24, 2006
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Wayne Godfrey, Edgar G. Engleman
  • Patent number: 7115800
    Abstract: The present invention is a novel method which results in the production of small seedless watermelon fruit having an average fruit weight of less than 12.0 pounds. The novel method involves using small tetraploid parental lines to produce small triploid hybrid seed.
    Type: Grant
    Filed: December 18, 2002
    Date of Patent: October 3, 2006
    Assignee: Seminis Vegetable Seeds, Inc.
    Inventors: Robert Barham, Warren Barham, Fred T. McCuistion, Benito Juarez
  • Patent number: 7105730
    Abstract: This invention relates to the field of biotechnology, particularly as it pertains to the production of sterols in a variety of host systems particularly plants. More specifically, the invention relates to nucleic acid molecules encoding proteins and fragments of proteins associated with sterol and phytosterol metabolism as well as the encoded proteins and fragments of proteins and antibodies capable of binding to them. The invention also relates to methods of using the nucleic acid molecules, fragments of the nucleic acid molecules, proteins, and fragments of proteins. The invention also relates to cells, organisms, particularly plants, or seeds, or progeny of plants, that have been manipulated to contain increased levels or overexpress at least one sterol or phytosterol compound.
    Type: Grant
    Filed: July 11, 2000
    Date of Patent: September 12, 2006
    Assignee: Monsanto Technology L.L.C.
    Inventors: Balasulojini Karunanandaa, Jaehyuk Yu, Ganesh M. Kishore
  • Patent number: 7101853
    Abstract: Methods for treating or preventing gastritis or gastric injury are disclosed, comprising administering a therapeutically effective amount of an amylin or an amylin agonist. Methods are also disclosed for the treatment of pain, fever, inflammation, arthritis, hypercoagulability, or other conditions for which a non-steroidal anti-inflammatory drug would be indicated, comprising administering an amylin or amylin agonist in conjunction with administering a therapeutically effective amount of a non-steroidal anti-inflammatory agent. Pharmaceutical compositions comprising an amylin or amylin agonist and a non-steroidal anti-inflammatory drug are also disclosed.
    Type: Grant
    Filed: May 6, 1997
    Date of Patent: September 5, 2006
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventors: Andrew A. Young, Bronislava Gedulin, Gareth Wyn Beynon
  • Patent number: D536238
    Type: Grant
    Filed: August 18, 2004
    Date of Patent: February 6, 2007
    Assignee: Slimvac, Inc.
    Inventors: William P. Conley, Rodger Thomason